BHIVA and BIA guidelines for the treatment of Opportunistic Infection in HIV-seropositive Individuals 2011

Treatment of Opportunistic Infection in HIV-seropositive Individuals (2011) Introduction

Advances in the treatment of HIV infection with antiretroviral therapy have led to dramatic reductions in opportunistic infections and death. However, late presentation of HIV remains a problem and is a significant contributory cause to death in HIV-seropositive persons in the UK [1]. Furthermore, a recent UK Health Protection Agency (HPA) analysis showed that of 46 700 patients with diagnosed HIV, 19% had CD4 counts o200 cells/mL [2] and therefore remain at significant risk of opportunistic infection.

These guidelines have been drawn up to help physicians investigate and manage HIV-seropositive patients suspected of, or having an opportunistic infection (OI). They are primarily intended to guide practice in the UK and related health systems.

Downloads

British HIV Association and British Infection Association Guidelines for the Treatment of Opportunistic Infection in HIV-seropositive Individuals 2011

Writing Group

M Nelson, DH Dockrell and S Edwards on behalf of the BHIVA Guidelines Subcommittee
(See Appendix 2 for list of members of the BHIVA Guidelines Writing Group on Opportunistic Infection)

Reference

HIV Medicine (2011), 12 (Suppl. 2), 1-140.